3-Methylglutaric Acid

When your cells struggle to make energy, or when one of the steps that breaks down a protein building block called leucine is blocked, a small chemical called 3-methylglutaric acid (3-MG) starts spilling into your urine. Most people excrete only trace amounts. A persistent rise can be the first quiet signal that something deeper is off in the energy-producing parts of your cells.

This is a specialized organic acid test, not a screening blood panel. It is most often used to investigate unexplained neurological, muscular, or metabolic problems, but a result can also surface findings that ordinary labs (chemistry panels, CBC, even acylcarnitine profiles) would miss entirely.

What This Test Actually Measures

The assay quantifies 3-MG in a urine sample, typically reported relative to creatinine to correct for hydration. It is almost always interpreted alongside a closely related cousin, 3-methylglutaconic acid (3-MGA), and a fuller urine organic acid panel. The two acids share a metabolic origin and tend to rise together.

3-MG itself is a small organic acid produced when 3-methylglutaconyl-CoA, an intermediate in the leucine breakdown pathway, undergoes a side reaction (reduction of a double bond) instead of continuing down the main pathway. In healthy people, the leucine pathway processes this intermediate cleanly, and very little 3-MG escapes into urine. When the pathway breaks, or when the cell's energy machinery is stressed, the backup shows up here.

This Is a Niche, Specialist Marker

3-MG belongs in the category of research and specialist-clinical markers. There are no universally standardized reference cutpoints for healthy adults, and no large outcome studies link specific levels to disease risk in the general population. Clinical use is concentrated in metabolic and mitochondrial medicine, where it functions as a flag that prompts further workup rather than as a standalone diagnosis.

This means a single reading should never drive a clinical conclusion. Patterns matter more than any one number, and results need to be read in the context of symptoms, family history, and the broader organic acid profile.

Inherited Defects in Leucine Breakdown

The clearest reason 3-MG rises in urine is a primary inherited defect in the leucine breakdown pathway. The two best-studied conditions are 3-methylglutaconic aciduria type I (caused by mutations in a gene called AUH) and HMG-CoA lyase deficiency. Both produce a characteristic urine pattern: high 3-MG along with 3-methylglutaconic acid and, in the case of HMG-CoA lyase deficiency, very high 3-hydroxy-3-methylglutaric acid as well.

HMG-CoA lyase deficiency commonly presents in the newborn period, with roughly half of cases declaring themselves in the first weeks of life and a substantial proportion presenting later in the first year. The classic picture is low blood sugar that fails to produce ketones, vomiting, and metabolic acidosis. Type I 3-methylglutaconic aciduria can range from mild clumsiness and speech delay in childhood to adult-onset cerebellar ataxia and white matter changes in the brain. A delayed or missed diagnosis in these conditions is common, which is why the urine pattern matters.

Mitochondrial and Membrane Disorders

The second major reason 3-MG climbs is not a leucine pathway defect at all. It is a sign that the energy-producing compartments inside your cells (mitochondria) are struggling. The leading proposed mechanism is the so-called acetyl-CoA diversion pathway: when the cell's main energy cycle slows down, acetyl-CoA builds up and is diverted to form 3-methylglutaconyl-CoA from scratch, with 3-MG ending up in urine as a byproduct. An alternative hypothesis suggests a peroxisomal (rather than mitochondrial) source. The exact mechanism is still debated.

In a series of 977 patients investigated for metabolic disease, 3-methylglutaconic aciduria appeared in about 3% of all urine organic acid profiles, and in 11% of patients with genetically confirmed mitochondrial disorders. The pattern is especially common in two related groups of conditions: disorders of mitochondrial phospholipid remodeling, such as Barth syndrome (TAZ gene) and SERAC1-related MEGDEL syndrome, and disorders involving other mitochondrial membrane-associated proteins, including OPA3, DNAJC19, and TMEM70 defects.

Barth Syndrome

Barth syndrome is worth singling out because the urine pattern can be deceptive. Affected infants with cardiomyopathy have shown normal urine organic acids initially, with 3-methylglutaconic aciduria emerging only 6 to 18 months later. In one infantile case, careful quantification of both 3-MGA and 3-MG separated a borderline patient from age-matched controls who would otherwise have looked normal.

The practical implication: a single qualitative urine organic acid screen that comes back normal does not rule out Barth syndrome or related disorders. Repeat, quantitative measurement of both acids is sometimes needed to catch the pattern.

Other Conditions Where 3-MG Has Appeared

Beyond classic inborn errors, modestly elevated 3-MG and 3-MGA have shown up in several other contexts. In children with unexplained developmental language delay, mild elevations have been reported as a possible marker of an as-yet undefined metabolic disorder. In a subset of children on the autism spectrum, mitochondrial dysfunction has been linked to elevations in urinary 3-methylglutaconic and related organic acids, though the underlying studies vary in how directly they measured these markers. In glycogen storage disease type I, increased urinary 3-methylglutarate has been interpreted as evidence of mitochondrial impairment tied to insulin resistance.

A prospective study of urinary metabolites and kidney cancer risk found a weak inverse association between a combined 3-methylglutarate plus 2-methylglutarate signal and subsequent kidney cancer, with stronger findings when sampling was closer to diagnosis. The confidence intervals were wide and the authors called for replication, so this should not be read as a screening tool for cancer risk.

Reconciling a Nonspecific Marker

On its face, the evidence can feel contradictory: 3-MG is both a hallmark of specific inherited diseases AND a general flag for mitochondrial stress. Both are true. The way to hold these together is to treat 3-MG as a pattern indicator, not a single-disease test. The clinical meaning of a high result depends entirely on the company it keeps in the rest of the organic acid profile, the acylcarnitine pattern, and the clinical picture. Marked, persistent elevation with other leucine pathway acids points toward a primary enzyme defect. Modest, recurrent elevation alongside lactic acidosis or neurological symptoms points toward broader mitochondrial dysfunction.

Why Serial Testing Matters

Excretion of 3-MG is not steady. In many secondary 3-methylglutaconic acidurias, urinary excretion is highly variable and intermittently absent, and a level on any given day does not reliably track how severe the underlying condition is. This is especially true for Barth syndrome, where the marker can be undetectable early on and only become apparent months later.

A single normal result, particularly from a one-time qualitative screen, should not close the door on a serious clinical suspicion. If your initial workup is being driven by unexplained symptoms or family history, plan for at least one repeat test, ideally with quantitative measurement of both 3-MG and 3-MGA. If you are using this as part of a broader metabolic baseline, retesting annually, or every 3 to 6 months if symptoms or context change, gives you a trajectory rather than a snapshot.

When Results Can Be Misleading

A few factors can distort a single reading or make it hard to interpret in isolation.

• Sample timing and variability: in many secondary 3-methylglutaconic acidurias, excretion fluctuates day to day and can be intermittently absent, so a single normal sample does not exclude disease.
• Hydration and creatinine correction: because results are reported relative to creatinine, very dilute or very concentrated urine can shift the apparent number even when the underlying biology has not changed.
• Acute metabolic stress: elevations can appear during decompensation of other inherited metabolic conditions (organic acidurias, urea cycle disorders, glycogen storage disease type I), reflecting mitochondrial overload rather than a primary 3-MG pathway defect.
• Single qualitative screens: a routine qualitative organic acid screen can miss borderline elevations that quantitative measurement of both 3-MG and 3-MGA would catch.

What to Do With an Out-of-Pattern Result

A high or unexpected result is the start of a workup, not a conclusion. The standard next step is a full urine organic acid profile by gas chromatography-mass spectrometry if one was not already done, ideally repeated on a separate sample to confirm the pattern. A plasma acylcarnitine profile by tandem mass spectrometry is usually ordered alongside, because characteristic acylcarnitines can clinch the diagnosis of HMG-CoA lyase deficiency and other organic acidemias.

Basic supporting labs that round out the picture include plasma amino acids, lactate, ammonia, and a basic chemistry panel to look for acidosis or low blood sugar. If the biochemical pattern points toward a specific disorder, the next step is usually genetic testing (targeted panels for AUH, HMGCL, TAZ, SERAC1, OPA3, DNAJC19, TMEM70, or YME1L1, or whole exome sequencing) and, where available, direct enzyme activity assays.

This is the right point to bring in a metabolic geneticist or biochemical genetics specialist. Pattern interpretation in this space is highly specialized, and the difference between a primary enzyme defect and a secondary mitochondrial finding changes everything about what comes next.